![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background: IL-21, a recently described common γ-chain cytokine, can induce the maturation and enhanced cytotoxicity of natural killer (NK) and CD8+ T cells and proliferation of CD40-stimulated B cells. Exogenous IL-21 has antitumor effects in murine models via immunological mechanisms. In addition, IL-21 can also directly induce apoptosis in chronic lymphocytic leukemia cells and other B cell lymphomas. Objective/methods: We examine preclinical and clinical data regarding anticancer therapy with IL-21. Published original research, abstracts and ongoing clinical trials are reviewed. A brief summary of IL-21 biology is also provided. Conclusion: Three Phase I and II clinical trials with recombinant IL-21 have been completed, providing data on the safety and efficacy in subjects with advanced melanoma, renal cell carcinoma and non-Hodgkin's B cell lymphoma. Numerous additional single-agent and combination therapy clinical trials are ongoing for a variety of human malignancies. B cell malignancies in particular warrant further clinical investigation.
Acknowledgements
JM Timmerman is the recipient of a Clinical Investigator Award from the Damon Runyon Cancer Research Foundation. DJ Andorsky is supported by grant T32 HL66992 from the National Institutes of Health, Bethesda, MD, USA.